Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by T Dort
Pnd55 - A Cost-Effectiveness Analysis Using Real-World Data From the Msbase Registry: Comparing Natalizumab to Fingolimod in Patients With Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in Italy
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pnd56 - A Cost-Effectiveness Analysis Using Real-World Data From the Msbase Registry: Comparing Natalizumab to Fingolimod in Patients With Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in Spain
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Related publications
Real-Life Effectiveness of Natalizumab in Relapsing-Remitting Multiple Sclerosis (Rrms): A Registry Analysis
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Efficacy of Natalizumab and Fingolimod in Relapsing Remitting Multiple Sclerosis in Real World Clinical Setting
Journal of Neurology & Neurophysiology
Disease-Modifying Therapies in Relapsing–remitting Multiple Sclerosis
Neuropsychiatric Disease and Treatment
Psychiatry
Mental Health
Biological Psychiatry
Comparing the Quality of Life Among Patients With Relapsing Remitting Multiple Sclerosis in Iraq Using Different Disease Modifying Therapies
Iraqi Journal of Pharmaceutical Sciences
Toxicology
Analytical Chemistry
Pharmaceutics
Pharmacology
The Real-World Effectiveness and Safety of Fingolimod in Relapsing-Remitting Multiple Sclerosis Patients: An Observational Study
PLoS ONE
Multidisciplinary
Long-Term Evaluation of NEDA-3 Status in Relapsing-Remitting Multiple Sclerosis Patients After Switching From Natalizumab to Fingolimod
Therapeutic Advances in Neurological Disorders
Neurology
Pharmacology
Comparing the Cost-Effectiveness of Disease-Modifying Drugs for the First-Line Treatment of Relapsing-Remitting Multiple Sclerosis
Journal of Managed Care Pharmacy
Correction To: Switching From Natalizumab to Fingolimod Treatment in Multiple Sclerosis: Real Life Data From the Austrian MS Treatment Registry
Journal of Neurology
Neurology
